Our series of studies demonstrated that ARF6 and its downstream effector AMAP1 are often overexpressed in different cancers, including PDAC, and this overexpression is statistically correlated with the poor prognosis of cancer patients [21,28,160,161,162]. This evidence concerns the gene ARF6 and cancer.